Publication Information

{'id': 'https://openalex.org/W2999426854', 'doi': 'https://doi.org/10.4155/tde-2019-0098', 'title': 'Utilizing nanotechnology to recuperate sorafenib for lung cancer treatment: challenges and future perspective', 'display_name': 'Utilizing nanotechnology to recuperate sorafenib for lung cancer treatment: challenges and future perspective', 'publication_year': 2020, 'publication_date': '2020-01-15', 'ids': {'openalex': 'https://openalex.org/W2999426854', 'doi': 'https://doi.org/10.4155/tde-2019-0098', 'mag': '2999426854', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/31937209'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.4155/tde-2019-0098', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S89829989', 'display_name': 'Therapeutic Delivery', 'issn_l': '2041-5990', 'issn': ['2041-5990', '2041-6008'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320316', 'host_organization_name': 'Future Science Ltd', 'host_organization_lineage': ['https://openalex.org/P4310320316'], 'host_organization_lineage_names': ['Future Science Ltd'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'editorial', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5000476704', 'display_name': 'Snehal K. Shukla', 'orcid': 'https://orcid.org/0000-0001-5530-1992'}, 'institutions': [{'id': 'https://openalex.org/I142823887', 'display_name': "St. John's University", 'ror': 'https://ror.org/00bgtad15', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I142823887']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Snehal K Shukla', 'raw_affiliation_strings': ['College of Pharmacy & Health Sciences\r8000 Utopia Parkway\rSt John’s University\rQueens\rNY\r11439\rUSA'], 'affiliations': [{'raw_affiliation_string': 'College of Pharmacy & Health Sciences\r8000 Utopia Parkway\rSt John’s University\rQueens\rNY\r11439\rUSA', 'institution_ids': ['https://openalex.org/I142823887']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5039112637', 'display_name': 'Vivek Gupta', 'orcid': 'https://orcid.org/0000-0002-3618-8178'}, 'institutions': [{'id': 'https://openalex.org/I142823887', 'display_name': "St. John's University", 'ror': 'https://ror.org/00bgtad15', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I142823887']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Vivek Gupta', 'raw_affiliation_strings': ['College of Pharmacy & Health Sciences\r8000 Utopia Parkway\rSt John’s University\rQueens\rNY\r11439\rUSA'], 'affiliations': [{'raw_affiliation_string': 'College of Pharmacy & Health Sciences\r8000 Utopia Parkway\rSt John’s University\rQueens\rNY\r11439\rUSA', 'institution_ids': ['https://openalex.org/I142823887']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': None, 'has_fulltext': False, 'cited_by_count': 5, 'citation_normalized_percentile': {'value': 0.437991, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 79, 'max': 81}, 'biblio': {'volume': '11', 'issue': '4', 'first_page': '213', 'last_page': '215'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T12334', 'display_name': 'Lung Cancer Research Studies', 'score': 0.997, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T12334', 'display_name': 'Lung Cancer Research Studies', 'score': 0.997, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9928, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T12505', 'display_name': 'Peptidase Inhibition and Analysis', 'score': 0.9923, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [], 'concepts': [{'id': 'https://openalex.org/C2778695046', 'wikidata': 'https://www.wikidata.org/wiki/Q421136', 'display_name': 'Sorafenib', 'level': 3, 'score': 0.8410728}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.63615465}, {'id': 'https://openalex.org/C2776256026', 'wikidata': 'https://www.wikidata.org/wiki/Q47912', 'display_name': 'Lung cancer', 'level': 2, 'score': 0.561014}, {'id': 'https://openalex.org/C2779473830', 'wikidata': 'https://www.wikidata.org/wiki/Q1540899', 'display_name': 'MEDLINE', 'level': 2, 'score': 0.48043227}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.44166172}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.41638082}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.36835733}, {'id': 'https://openalex.org/C2778019345', 'wikidata': 'https://www.wikidata.org/wiki/Q1148337', 'display_name': 'Hepatocellular carcinoma', 'level': 2, 'score': 0.34242874}, {'id': 'https://openalex.org/C86803240', 'wikidata': 'https://www.wikidata.org/wiki/Q420', 'display_name': 'Biology', 'level': 0, 'score': 0.10351059}, {'id': 'https://openalex.org/C55493867', 'wikidata': 'https://www.wikidata.org/wiki/Q7094', 'display_name': 'Biochemistry', 'level': 1, 'score': 0.0}], 'mesh': [{'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D008175', 'descriptor_name': 'Lung Neoplasms', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D036103', 'descriptor_name': 'Nanotechnology', 'qualifier_ui': 'Q000639', 'qualifier_name': 'trends', 'is_major_topic': True}, {'descriptor_ui': 'D000077157', 'descriptor_name': 'Sorafenib', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D045744', 'descriptor_name': 'Cell Line, Tumor', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008175', 'descriptor_name': 'Lung Neoplasms', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D036103', 'descriptor_name': 'Nanotechnology', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000077157', 'descriptor_name': 'Sorafenib', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.4155/tde-2019-0098', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S89829989', 'display_name': 'Therapeutic Delivery', 'issn_l': '2041-5990', 'issn': ['2041-5990', '2041-6008'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320316', 'host_organization_name': 'Future Science Ltd', 'host_organization_lineage': ['https://openalex.org/P4310320316'], 'host_organization_lineage_names': ['Future Science Ltd'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/31937209', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.78, 'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 19, 'referenced_works': ['https://openalex.org/W1984816940', 'https://openalex.org/W1997303727', 'https://openalex.org/W2015006203', 'https://openalex.org/W2023187096', 'https://openalex.org/W2042249858', 'https://openalex.org/W2054728384', 'https://openalex.org/W2126263799', 'https://openalex.org/W2135440815', 'https://openalex.org/W2159370421', 'https://openalex.org/W2193867915', 'https://openalex.org/W2304373741', 'https://openalex.org/W2462860447', 'https://openalex.org/W2755425308', 'https://openalex.org/W2767688560', 'https://openalex.org/W2771155547', 'https://openalex.org/W2784279077', 'https://openalex.org/W2921127261', 'https://openalex.org/W2944822110', 'https://openalex.org/W3145590951'], 'related_works': ['https://openalex.org/W4361816912', 'https://openalex.org/W4285206599', 'https://openalex.org/W3018861914', 'https://openalex.org/W2769323635', 'https://openalex.org/W2415536161', 'https://openalex.org/W2329980328', 'https://openalex.org/W2087356637', 'https://openalex.org/W2034139851', 'https://openalex.org/W1980459335', 'https://openalex.org/W1970460092'], 'abstract_inverted_index': {'Therapeutic': [0], 'DeliveryVol.': [1], '11,': [2, 790], 'No.': [3, 787, 791], '4': [4, 792], 'EditorialUtilizing': [5], 'nanotechnology': [6, 714], 'to': [7, 75, 209, 410, 449, 537, 850, 862], 'recuperate': [8], 'sorafenib': [9, 99, 128, 167, 237, 297, 344, 407, 605], 'for': [10, 43, 100, 374, 481, 604, 661, 690, 754, 798], 'lung': [11, 85, 132, 200, 244, 307, 348, 627, 640, 691, 830], 'cancer': [12, 86, 133, 201, 245, 308, 831], 'treatment:': [13], 'challenges': [14], 'and': [15, 96, 135, 203, 233, 339, 439, 452, 634, 642, 718, 741], 'future': [16], 'perspectiveSnehal': [17], 'K': [18, 23], 'Shukla': [19, 854], '&': [20, 27, 40, 55, 835], 'Vivek': [21, 41], 'GuptaSnehal': [22], 'ShuklaCollege': [24], 'of': [25, 53, 98, 103, 127, 166, 195, 254, 279, 296, 337, 378, 406, 441, 455, 502, 555, 579, 626, 631, 636, 664, 694, 713, 734, 744, 748, 756, 766, 908], 'Pharmacy': [26, 54], 'Health': [28, 56], 'Sciences,': [29, 57], '8000': [30, 58], 'Utopia': [31, 59], 'Parkway,': [32, 60], 'St': [33, 61], "John's": [34, 62], 'University,': [35, 63], 'Queens,': [36, 64], 'NY': [37, 65], '11439,': [38, 66], 'USA': [39], 'Gupta*Author': [42], 'correspondence:': [44], 'Tel.:': [45], '+1': [46], '718': [47], '990': [48], '3929;': [49], 'E-mail': [50], 'Address:': [51], '[email protected]': [52], 'USAPublished': [67], 'Online:15': [68], 'Jan': [69], '2020https://doi.org/10.4155/tde-2019-0098AboutSectionsView': [70], 'ArticleView': [71], 'Full': [72], 'TextPDF/EPUB': [73], 'ToolsAdd': [74], 'favoritesDownload': [76], 'CitationsTrack': [77], 'CitationsPermissionsReprints': [78], 'ShareShare': [79], 'onFacebookTwitterLinkedInReddit': [80], 'View': [81], 'articleKeywords:': [82], 'formulation': [83], 'approachesnanocarriersnon-small-cell': [84, 829], '(NSCLC)pulmonary': [87, 832], 'deliverysorafenibtyrosine-kinase': [88, 833], 'inhibitorReferences1.': [89], 'White': [90], 'PT,': [91], 'Cohen': [92], 'MS.': [93], 'The': [94, 865], 'discovery': [95], 'development': [97, 554], 'the': [101, 255, 385, 629, 695, 799, 888, 895, 906], 'treatment': [102, 314, 625, 663, 755], 'thyroid': [104], 'cancer.': [105, 349], 'Expert': [106], 'Opin.': [107], 'Drug': [108, 669], 'Discov.': [109], '10(4),': [110], '427–439': [111], '(2015).Crossref,': [112, 461, 545], 'Medline,': [113, 152, 181, 220, 266, 356, 393, 426, 489, 518, 546, 563, 591, 613, 675], 'CAS,': [114, 182, 221, 322, 357, 394, 427, 462, 490, 519, 547, 564, 650, 676, 703], 'Google': [115, 153, 183, 222, 267, 323, 358, 395, 428, 463, 491, 520, 548, 565, 592, 614, 651, 677, 704], 'Scholar2.': [116], 'Casadei': [117], 'Gardini': [118], 'A,': [119, 156], 'Chiadini': [120], 'E,': [121], 'Faloppi': [122], 'L': [123, 274], 'et': [124, 161, 191, 230, 275, 332, 403, 436, 499, 600, 685], 'al.': [125, 162, 192, 231, 276, 333, 404, 437, 500, 601, 686], 'Efficacy': [126], 'in': [129, 138, 168, 198, 239, 281, 298, 345, 553, 582, 715, 730, 821, 883, 894, 905], 'BRAF-mutated': [130], 'non-small-cell': [131, 243, 306, 347], '(NSCLC)': [134], 'no': [136, 868], 'response': [137], 'synchronous': [139], 'BRAF': [140], 'wild': [141], 'type-hepatocellular': [142], 'carcinoma:': [143], 'a': [144, 249, 290, 415, 445, 577, 880], 'case': [145], 'report.': [146], 'BMC': [147], 'Cancer': [148, 216, 262, 287, 532, 575, 644], '16(1),': [149], '429': [150], '(2016).Crossref,': [151], 'Scholar3.': [154], 'Guidetti': [155], 'Carlo‐Stella': [157], 'C,': [158], 'Locatelli': [159], 'SL': [160], 'Phase': [163, 251, 291, 334], 'II': [164, 252], 'study': [165, 253, 336], 'patients': [169, 240, 299], 'with': [170, 206, 241, 300, 343, 874, 879, 887], 'relapsed': [171, 301], 'or': [172, 236, 302, 311, 342, 871, 877, 884, 891], 'refractory': [173, 303], 'lymphoma.': [174], 'Br.': [175, 214], 'J.': [176, 215, 316, 350, 421, 513, 559], 'Haematol.': [177], '158(1),': [178], '108–119': [179], '(2012).Crossref,': [180, 562], 'Scholar4.': [184], 'Morgillo': [185], 'F,': [186], 'Cascone': [187], 'T,': [188, 494, 654], "D'Aiuto": [189], 'E': [190], 'Antitumour': [193], 'efficacy': [194, 743], 'MEK': [196], 'inhibitors': [197], 'human': [199], 'cells': [202], 'their': [204, 639], 'derivatives': [205], 'acquired': [207], 'resistance': [208], 'different': [210], 'tyrosine': [211, 380], 'kinase': [212, 381], 'inhibitors.': [213], '105(3),': [217], '382–392': [218], '(2011).Crossref,': [219], 'Scholar5.': [223], 'Spigel': [224], 'DR,': [225], 'Rubin': [226], 'MS,': [227], 'Gian': [228], 'VG': [229], 'Sorafenib': [232, 280], 'continued': [234], 'erlotinib': [235], 'alone': [238, 341], 'advanced': [242, 346], 'progressing': [246], 'on': [247, 384, 638, 795], 'erlotinib:': [248], 'randomized': [250], 'Sarah': [256], 'Cannon': [257], 'Research': [258, 845], 'Institute': [259], '(SCRI).': [260], 'Lung': [261, 286, 778], '113,': [263], '79–84': [264], '(2017).Crossref,': [265, 590], 'Scholar6.': [268], 'Paz-Ares': [269], 'L,': [270, 597, 656], 'Hirsh': [271], 'V,': [272, 466, 470], 'Zhang': [273, 526], 'Monotherapy': [277], 'Administration': [278], 'Patients': [282], 'With': [283], 'Non–Small': [284], 'Cell': [285, 777], '(MISSION)': [288], 'trial:': [289], 'III,': [292], 'multicenter,': [293], 'placebo-controlled': [294], 'trial': [295], 'predominantly': [304], 'nonsquamous': [305], 'after': [309], '2': [310], '3': [312, 788], 'previous': [313], 'regimens.': [315], 'Thorac.': [317], 'Oncol.': [318, 352], '10(12),': [319], '1745–1753': [320], '(2015).Medline,': [321, 702], 'Scholar7.': [324], 'Scagliotti': [325], 'G,': [326, 496, 619], 'Novello': [327], 'S,': [328, 568, 595, 682], 'von': [329], 'Pawel': [330], 'J': [331], 'III': [335], 'carboplatin': [338], 'paclitaxel': [340], 'Clin.': [351, 388, 585], '28(11),': [353], '1835–1842': [354], '(2010).Crossref,': [355], 'Scholar8.': [359], 'Yu': [360], 'H,': [361], 'Steeghs': [362], 'N,': [363, 529], 'Nijenhuis': [364], 'CM,': [365], 'Schellens': [366], 'JHM,': [367], 'Beijnen': [368], 'JH,': [369], 'Huitema': [370], 'ADR.': [371], 'Practical': [372], 'guidelines': [373], 'therapeutic': [375], 'drug': [376, 583, 709], 'monitoring': [377], 'anticancer': [379], 'inhibitors:': [382], 'focus': [383], 'pharmacokinetic': [386], 'targets.': [387], 'Pharmacokinet.': [389], '53(4),': [390], '305–325': [391], '(2014).Crossref,': [392], 'Scholar9.': [396], 'Park': [397], 'SY,': [398], 'Kang': [399], 'Z,': [400], 'Thapa': [401], 'P': [402], 'Development': [405], 'loaded': [408], 'nanoparticles': [409], 'improve': [411], 'oral': [412, 453], 'bioavailability': [413, 454], 'using': [414, 444, 506], 'quality': [416], 'by': [417, 842, 857], 'design': [418], 'approach.': [419], 'Int.': [420, 512], 'Pharm.': [422, 514], '566,': [423], '229–238': [424], '(2019).Crossref,': [425, 517], 'Scholar10.': [429], 'Truong': [430], 'DH,': [431], 'Tran': [432, 567], 'TH,': [433], 'Ramasamy': [434], 'T': [435], 'Preparation': [438, 501], 'characterization': [440], 'solid': [442], 'dispersion': [443], 'novel': [446, 708], 'amphiphilic': [447], 'copolymer': [448], 'enhance': [450], 'dissolution': [451], 'sorafenib.': [456, 482], 'Powder': [457], 'Technol.': [458], '283,': [459], '260–265': [460], 'Scholar11.': [464], 'Giglio': [465], 'Viale': [467], 'M,': [468], 'Bertone': [469], 'Maric': [471], 'I,': [472], 'Vaccarone': [473], 'R,': [474], 'Vecchio': [475], 'G.': [476], 'Cyclodextrin': [477], 'polymers': [478], 'as': [479, 724], 'nanocarriers': [480, 603, 637], 'Invest.': [483], 'New': [484], 'Drugs': [485], '36(3),': [486], '370–379': [487], '(2018).Crossref,': [488, 612], 'Scholar12.': [492], 'Feczkó': [493], 'Merza': [495], 'Babos': [497], 'G': [498], 'cubic-shaped': [503], 'sorafenib-loaded': [504], 'nanocomposite': [505], 'well-defined': [507], 'poly(vinyl': [508], 'alcohol': [509], 'alt-propenylene)': [510], 'copolymer.': [511], '562,': [515], '333–341': [516], 'Scholar13.': [521], 'Xu': [522], 'X,': [523, 527], 'Ho': [524], 'W,': [525], 'Bertrand': [528], 'Farokhzad': [530], 'O.': [531], 'nanomedicine:': [533, 576], 'from': [534, 860, 898], 'targeted': [535, 725], 'delivery': [536, 710, 726], 'combination': [538], 'therapy.': [539], 'Trends': [540], 'Mol': [541], 'Med.': [542, 587, 646], '21(4),': [543], '223–232': [544], 'Scholar14.': [549], 'Desai': [550], 'N.': [551], 'Challenges': [552], 'nanoparticle-based': [556], 'therapeutics.': [557], 'AAPS': [558], '14(2),': [560], '282–295': [561], 'Scholar15.': [566], 'DeGiovanni': [569], 'P-J,': [570], 'Piel': [571], 'B,': [572], 'Rai': [573], 'P.': [574], 'review': [578], 'recent': [580], 'success': [581], 'delivery.': [584, 606], 'Transl.': [586], '6(1),': [588], '44': [589], 'Scholar16.': [593], 'Benizri': [594], 'Ferey': [596], 'Alies': [598], 'B': [599], 'Nucleoside-lipid-based': [602], 'Nanoscale': [607], 'Res.': [608], 'Lett.': [609], '13(1),': [610], '17': [611], 'Scholar17.': [615], 'Garbuzenko': [616], 'OB,': [617], 'Mainelis': [618], 'Taratula': [620], 'O,': [621], 'Minko': [622, 653], 'T.': [623], 'Inhalation': [624], 'cancer:': [628, 692], 'influence': [630], 'composition,': [632], 'size': [633], 'shape': [635], 'accumulation': [641], 'retention.': [643], 'Biol.': [645], '11(1),': [647], '44–55': [648], '(2014).Medline,': [649], 'Scholar18.': [652], 'Rodriguez-Rodriguez': [655], 'Pozharov': [657], 'V.': [658], 'Nanotechnology': [659], 'approaches': [660], 'personalized': [662], 'multidrug': [665], 'resistant': [666], 'cancers.': [667], 'Adv.': [668], 'Deliv.': [670], 'Rev.': [671], '65(13–14),': [672], '1880–1895': [673], '(2013).Crossref,': [674], 'Scholar19.': [678], 'Ahmad': [679], 'J,': [680], 'Akhter': [681], 'Rizwanullah': [683], 'M': [684], 'Nanotechnology-based': [687], 'inhalation': [688], 'treatments': [689], 'state': [693], 'art.': [696], 'Nanotechnol': [697], 'Sci.': [698], 'Appl.': [699], '8,': [700], '55–66': [701], 'ScholarFiguresReferencesRelatedDetailsCited': [705], 'BySorafenib': [706], 'tosylate': [707], 'systems:': [711], 'Implications': [712], 'both': [716], 'approved': [717], 'unapproved': [719], 'indicationsOpenNano,': [720], 'Vol.': [721, 736, 751, 769, 785, 789], '8Liposomal': [722], 'doxorubicin': [723], 'platform:': [727], 'Current': [728], 'trends': [729], 'surface': [731], 'functionalizationInternational': [732], 'Journal': [733, 765], 'Pharmaceutics,': [735], '593Enhanced': [737], 'solubility,': [738], 'stability,': [739], 'permeation': [740], 'anti-cancer': [742], 'Celastrol-β-cyclodextrin': [745], 'inclusion': [746], 'complexJournal': [747], 'Molecular': [749], 'Liquids,': [750], '318Metformin-loaded': [752], 'chitosomes': [753], 'malignant': [757], 'pleural': [758], 'mesothelioma': [759], '–': [760], 'A': [761], 'rare': [762], 'thoracic': [763], 'cancerInternational': [764], 'Biological': [767], 'Macromolecules,': [768], '160Sorafenib': [770], 'Loaded': [771], 'Inhalable': [772], 'Polymeric': [773], 'Nanocarriers': [774], 'against': [775], 'Non-Small': [776], 'Cancer12': [779], 'March': [780], '2020': [781, 819, 824, 826], '|': [782], 'Pharmaceutical': [783], 'Research,': [784], '37,': [786], 'Follow': [793], 'us': [794], 'social': [796], 'media': [797], 'latest': [800], 'updates': [801], 'Metrics': [802], 'Downloaded': [803], '84': [804], 'times': [805], 'History': [806], 'Received': [807], '18': [808], 'December': [809, 813], '2019': [810, 814], 'Accepted': [811], '20': [812], 'Published': [815, 820], 'online': [816], '15': [817], 'January': [818], 'print': [822], 'April': [823], 'Information©': [825], 'Newlands': [827], 'PressKeywordsformulation': [828], 'inhibitorFinancial': [834], 'competing': [836], "interests'": [837], 'disclosureThis': [838], 'work': [839], 'was': [840, 855, 903], 'supported': [841, 856], 'an': [843], 'NIH': [844], 'Enhancement': [846], 'Award': [847], '(R15),': [848], '1R15HL138606-01A1': [849], 'V': [851, 863], 'Gupta.': [852, 864], 'SK': [853], 'research': [858], 'assistantship': [859], 'NIH-R15': [861], 'authors': [866], 'have': [867], 'relevant': [869], 'affiliations': [870], 'financial': [872, 881, 885], 'involvement': [873], 'any': [875], 'organization': [876], 'entity': [878], 'interest': [882], 'conflict': [886], 'subject': [889], 'matter': [890], 'materials': [892], 'discussed': [893], 'manuscript': [896], 'apart': [897], 'those': [899], 'disclosed.No': [900], 'writing': [901], 'assistance': [902], 'utilized': [904], 'production': [907], 'this': [909], 'manuscript.PDF': [910], 'download': [911]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2999426854', 'counts_by_year': [{'year': 2022, 'cited_by_count': 1}, {'year': 2020, 'cited_by_count': 4}], 'updated_date': '2024-12-12T09:03:56.459541', 'created_date': '2020-01-23'}